San Francisco, CA (PRWEB) May 05, 2012

Doobons.com and Idrasil announced today a strategic partnership to market Idrasil, the groundbreaking medical marijuana pill, on the Doobons.com website (see Idrasil tab).

Idrasils standardized formula delivers a consistent potency and arms patients with the ability to medicate themselves while achieving the same results every timejust like any other standardized pharmaceutical.

Idrasil is currently available in California with a Doctors recommendation (List of Current Idrasil Doctors). Manufactured in a laboratory with 1:1:1 ratio of all natural CBD, CBN & THC. Idrasil is a tablet that allows smoking and non-smoking patients another option for Cannabinoid therapy.

Idrasil, a product of C3 Patients Association addresses a variety of ailments and conditions such as AIDS & Wasting Syndrome, Cancer, Fibromyalgia, Crohns Disease, Alzheimers, Glaucoma, Pain Management, MS, Parkinsons, Sleep Disorders, Anxiety, Depression and as an aid in easing dependency & withdrawal symptoms. For pain patients, who have not yet been introduced to opiates, Idrasil is an excellent first step to pain abatement. Cannabinoid use diminishes the possibility of opioid overdose, which is an important concern to all caregivers and their liable parties.

“We are very excited about our exclusive partnership with Doobons, a company dedicated to delivering up to date news and resources to seriously ill patients, said founder of Idrasil. Together, we have made the commitment to provide safe access and accurate medicine for patients.

Until now, medications like Marinol are made strictly from synthetic tetrahydrocannabinol (THC) only, said John at Doobons.com. Studies have proven that when THC is combined with additional key elements of cannabis, ultimate healing can occur. Idrasil contains the full spectrum of phytocannabinoids, a key element in reducing symptoms brought on by chronic illness.

According to Idrasil, phytocannabinoids are the naturally occurring cannabinoids present in cannabis. The most prevalent of these are THC, Cannabidiol (CBD) and Cannabinol (CBN). Additionally, there are over 85 phytocannabinoids present in cannabis and many of them have known medicinal qualities.

Idrasil carefully extracts the full-spectrum of phytocannabinoids using a proprietary technology that does not involve the use of oils, chemicals or other additives. The extract is then carefully measured into tablets, so every pill delivers the same amount of medication.

BENEFITS OF IDRASIL vs. RAW MEDICAL CANNABIS

1.

PVI, PeerView Institute for Medical Education – PeerView Hepatic and Biliary Disorders CME/CNE/CPE Video Podcast
from PeerView Hepatic and Biliary Disorders CME/CNE/CPE Video Podcast
Price: USD 0
View Details about PVI, PeerView Institute for Medical Education

Dr. Igor Galynker, Director, Family Center for Bipolar Disorders at Beth Israel Medical Center in New York City, discusses diagnostic and treatment options for bipolar disorders and manic depressive illness.

www.truehope.com Bipolar Disorder, Manic Depressive Disorder Truehope Lu R. Lu R. suffered with Bipolar disorder ( Manic Depression ) for years. She was on the verge of giving up on life after having no success with the standard medical treatments ( Pharmaceuticals ). Her friend pressured her into trying the Truehope Treatment supplement ( Empowerplus ) and program. She reluctantly tried it just to get her friend to leave her alone. After 6 weeks on Truehope’s Empowerplus she decided that life was worth living.
Video Rating: 5 / 5

Bristol, UK, Sydney and Newcastle, Australia (PRWEB UK) 4 April 2012

Abcam, together with The University of Newcastle and the Children’s Medical Research Institute, have today announced the expansion of their range of small molecule dynamin inhibitors for research. These are novel tools for investigating clathrin-mediated endocytosis and synaptic vesicle recycling and are available in the Abcam Biochemicals range. The agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.

The laboratories of Professor Adam McCluskey (University of Newcastle) and Professor Phil Robinson (Children’s Medical Research Institute) have developed a potent, cell permeable inhibitor of dynamin, Rhodadyn C10, which potently inhibits clathrin-mediated endocytosis via dynamin inhibition. The Rhodadyn C10 dynamin inhibitor was recently published in ACS Medicinal Chemistry Letters, by a collaboration involving scientists from the University of Newcastle, Childrens Medical Research Institute, Leibniz Institut f

Beverly Hills, CA (PRWEB) March 15, 2012

A series of studies conducted by researchers at the University of Michigan and funded by the National Institute on Drug Abuse (NIDA) show a significant and alarming link between alcoholism and prescription drug abuse. The NIDA-funded studies report that compared to those who do not drink at all, individuals suffering from alcoholism are 18 times more likely to abuse prescription drugs. Waismann Method

Manhasset , NY (Vocus) October 28, 2009

It has been known for several years that antipsychotic medications can cause weight gain in adults and increase the risk for serious metabolic disorders. Scientists at The Zucker Hillside Hospital and The Feinstein Institute for Medical Research embarked on a large study following children and adolescents who have been prescribed antipsychotic medicines for the first time and examining the impact they had on weight gain and metabolic changes. Indeed, researchers identified a worrisome degree of weight gain and caution their colleagues to take these changes seriously. Weight gain and changes in blood glucose and lipid metabolism can be precursors of diabetes, hypertension, metabolic syndrome, stroke and heart attack. The children tested were between 4-19 years old.

“The data sheds further light on the frequency and severity of weight gain associated with these newer antipsychotics,” said Christoph U. Correll, MD, medical director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital and a scientist in the Feinstein Institute’s Center for Psychiatric Neuroscience. “Our findings suggest increased caution in prescribing them to pediatric patients.”

The scientists studied 272 young people who had been prescribed antipsychotic medicines for a range of serious behavioral, mood and psychosis-related problems. The patients were prescribed one of a number of second-generation antipsychotics and followed over the first 12 weeks to assess changes in weight, blood glucose and lipids. At around 11 weeks, the young patients had gained an average of 19 pounds on the antipsychotic, olanzapine; 13.5 pounds on quetiapine; 11.9 pounds on risperidone; and 9.9 pounds on aripiprazole. By comparison, 15 patients who refused participation in the study or were not compliant with taking the antipsychotics were used as a control group and their weight gain during the same study period was less than a half-pound.

The findings were published this week in the Journal of the American Medical Association (JAMA).

The scientists also identified substantial changes in triglycerides and cholesterol, and found that the weight gain alone did not seem to explain entirely the adverse metabolic effects that varied significantly across the individual medications. All of the findings, Dr. Correll said, “should be considered when choosing antipsychotics.” SATIETY (Second-Generation Antipsychotic Treatment Indications, Effectiveness and Tolerability in Youth) is the largest cohort study of atypical antipsychotic treatment in children and adolescents treated with antipsychotics. It is also the largest study of its kind in children or adults who received antipsychotic treatment for the first time in their life. This is a key study feature because prior treatment can obscure the true cardiometabolic effects of medications. In the SATIETY study, the antipsychotic-na

Medical University of South Carolina – MUSC Mental Health Podcast
from MUSC Mental Health Podcast
Price: USD 0
View Details about Medical University of South Carolina

Exqisit Medical Meditation Series, Dr John McIntosh & Elizabeth Young – Medical Information
from Depression: Lifting The Clouds – Meditation
Price: USD -1
View Details about Exqisit Medical Meditation Series, Dr John McIntosh & Elizabeth Young

San Jose, CA (PRWEB) July 28, 2011

San Francisco Bay Area cannabis capsule company God Med is pushing the envelope of potency, with its latest batch of medical marijuana capsules (batch #2217) surpassing the 50 mg THC level. Each capsule of these medical cannabis pills contains 50.80 mg of THC and .83 mg of CBD, verified by testing from CW Analyticalan East Bay marijuana laboratory that ensures the quality and safety of medical marijuana products sold in dispensaries.

Steve Casebeer, founder of God Med, says his capsules potency levels are on the rise with 60 mg and 70 mg THC capsules expected in batches 2218 and 2219, respectively. These THC levels are twice as high as the level of THC in most competitors medical marijuana capsules.

God Med medicinal cannabis capsules are made from California Emerald Triangle outdoor-grown organic flowers, kief and non-genetically modified soy lecithin activated/decarboxylated in a near infrared (NIR) system. The vegan cannabis salad capsules benefits are enhanced by the addition of the soy emulsifier.

The synergy between the tetrahydrocannabinol (THC) and cannabidiol (CBD) in the capsules does not produce the stoned effect patients feel when they smoke or vaporize medical cannabis, said Casebeer. The whole plant in capsule form simply promotes an increased state of well-being as the natural medication improves the patients health.

Scientific research has found THC to be an effective treatment for a wide range of ailments, including Alzheimers disease, diabetes, dystonia (a neurological movement disorder that causes sustained muscle contractions, twisting and repetitive movements or abnormal postures), fibromyalgia, gliomas (brain tumors), incontinence, sleep apnea, and Tourettes syndrome, among others.

Cannabidiol (CBD) is a cannabinoid that can increase alertness and has been shown to relieve inflammation, anxiety, nausea and convulsions in patients. Research has shown CBD can be effective at inhibiting cancer cell growth, including breast cancer and gliomas. It has also been shown to reduce symptoms of Alzheimers disease, diabetes, dystonia, and schizophrenia. CBD also decreases the rate of clearance of tetrahydrocannabinol (THC) from the body, so that the effects last longer.

But it is the combination of THC and CBD, along with cannabinol (CBN) and the over 200 other medicinal compounds naturally occurring in the marijuana plant that has the greatest medical effect, with studies demonstrating effectiveness in treating chronic pain, HIV, incontinence, multiple sclerosis, pruritus (itching associated with various skin diseases), and rheumatoid arthritis.

God Med capsules contain the whole cannabis trichome, including the full spectrum of Phytocannabinoids, Terpenoids, Flavonoids, and Phytosteral components. They provide relief for a multitude of illnesses by becoming medicine the body needs, Casebeer explained.

God Med Cannabis Capsules are available at various locations, including San Francisco Bay Area medical marijuana dispensaries in the North Bay, South Bay and East Bay. For more information about Cannabis Capsules or any of God Meds services, view them on the web at http://godmed.com/.

About God Med

God Med is a medical marijuana company that specializes in the production of cannabis capsules. God Med serves the entire state of California, including the San Francisco Bay Area communities of Alameda, Antioch, Berkeley, Castro Valley, Concord, Daly City, Dublin, Emeryville, Fairfield, Fremont, Hayward, Livermore, Marin, Martinez, Mill Valley, Mountain View, Napa, Novato, Oakland, Palo Alto, Pleasanton, Redwood City, Richmond, San Bruno, San Francisco, San Jose, San Mateo, San Rafael, San Ramon, Santa Clara, Sonoma County, Solano County, Vacaville, Vallejo and Walnut Creek.

###

Find More Tourette’s Disorder Press Releases

Oakland, CA (PRWEB) February 05, 2012

In a major scientific development for the cannabis industry, an exciting and advanced new technology has recently been launched at the nations leading medical cannabis dispensary, Harborside Health Center, located in Oakland, California. Harborside is the first in the region to implement and utilize the new technology, QuantaCann, after months of beta testing and collaborations with developer Steep Hill Lab, an Oakland cannabis testing facility.

QuantaCanns new technology is an innovative software and scientific instrumentation system that is used on-site at dispensaries and collectives to test strains and provide quick results. In minutes, QuantaCann analyzes the strain, providing data about THC and CBD potency levels, moisture content, and many other components of the plant. In addition to other fields of critical strain-specific data, the system catalogs symptoms and medical conditions that the strains are being utilized for, providing a valuable database of information for future research.

This new system is a game changer for the entire industry, says Steve DeAngelo, the Executive Director of Harborside. Five years ago DeAngelo was looking for a lab to test medical cannabis for strain data, potency and chemistry to ensure he provided only the finest quality medical cannabis at his highly regarded Oakland medical cannabis club facility. No existing lab in Northern California would take this task on, so DeAngelo collaborated with engineer David Lampach and activist Addison DeMoura to create Steep Hill Lab, the nations first medical cannabis testing facility, in 2008. After testing over 2,100 strains of cannabis, 9 rare strains were found with solid levels of CBD, the component known to lessen the affects of inflammation, pain, anxiety and spasms without producing the psychoactive effect of the plant associated with THC.

Despite constant Federal vs. State intervention and confusion of the laws, the medical cannabis industry has now grown to 17 states and the District in Columbia with many ancillary businesses and services forming to support the now millions in the patient care community. With growing acceptance of and demand for medicinal cannabis, lab-tested and certified clean green medicine is a trend that has grown exponentially over the past few years.

QuantaCann uses Near-Infrared Reflective (NIR) spectroscopy to compare the data to thousands of samples from Steep Hills vast database, thereby allowing the machine to deliver test results in seconds. The system identifies CBD-rich strains, which have many benefits yet are extremely rare, making the QuantaCann system a valuable tool for any dispensary. Harborside has already discovered 5 new CBD strains since implementing QuantaCann.

The availability of the QuantaCann system to everyone in the cannabis industry is sure to revolutionize the safety and purchasing process, adding consistency and immediate results for dispensaries and patient-farmers growing the medicine. The database will grow as the system becomes available in all compassionate use states and could also greatly aid new studies and research. Harborside Health Center, in collaboration with Steep Hill Lab, once again breaks new ground for the industry.

For Harborside Media Relations, please contact Gaynell Rogers at (415) 298-1114 or gaynellrogers(at)gmail(dot)com.

About Harborside Health Center

Founded by national cannabis leader Steve DeAngelo in 2006, Harborside Health Center is the nations largest not-for-profit model medical cannabis dispensary. The Oakland medicinal cannabis collective offers its 104,000 registered patients free holistic healing services, lab tested medicine and education. Harborside was featured on the Discovery Channels miniseries Weed Wars in December of 2011.

Out of the shadows and into the light epitomizes DeAngelos mission to enlighten the public on the many medicinal and therapeutic benefits of the plant and actively works to empower the country to change its image of medical marijuana.

For more information about Harborside, call (510) 533-0146 or visit http://www.harborsidehealthcenter.com/.

###